Metagenomi Therapeutics (MGX) Enterprise Value (2024 - 2026)

Metagenomi Therapeutics (MGX) has reported Enterprise Value for 3 consecutive years, with -$75.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value rose 49.34% year-over-year to -$75.7 million in Q2 2026; TTM through Jun 2026 was -$75.7 million, a 49.34% increase from a year earlier, with the FY2025 full-year figure at -$99.9 million, up 11.81% from the prior year.
• Enterprise Value was -$75.7 million for Q2 2026 at Metagenomi Therapeutics, up from -$89.7 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$75.7 million in Q2 2026 and troughed at -$193.4 million in Q3 2024.
• A 3-year average of -$124.3 million and a median of -$108.8 million in 2024 frame the typical range for Enterprise Value.
• The widest YoY moves for Enterprise Value: up 50.8% in 2025, down 67.75% in 2025.
• Over 3 years, Enterprise Value stood at -$113.2 million in 2024, then climbed by 11.81% to -$99.9 million in 2025, then rose by 24.18% to -$75.7 million in 2026.
• The last three Enterprise Value figures came in at -$75.7 million (Q2 2026), -$89.7 million (Q1 2026), and -$99.9 million (Q4 2025), per Business Quant data.